Allergic
asthma therapeutics aims to treat patients suffering from allergic asthma
disorders through anti-inflammatory and bronchodilator drugs. Allergic asthma
refers to a type of asthma caused by an allergic reaction to inhaled allergens
such as dust mites, pollen, pet dander, or mold. The common symptoms include
chest tightness, wheezing, cough and shortness of breath. The global demand for
these therapeutics has been rising with increasing cases of allergic asthma
worldwide due to factors such as genetic predisposition and exposure to
allergens and air pollution. The therapeutics provide fast relief from asthma
exacerbations and improve the quality of life for patients.
The global Allergic Asthma Therapeutics Market is estimated to be valued at US$
8.37 Bn in 2024 and is expected to exhibit a CAGR of 13% over the forecast
period 2024 to 2031, as highlighted in a new report published by Coherent
Market Insights.
Market key trends:
The increasing research pipelines for novel biologics and targeted therapies
presents one of the major trends in the allergic asthma therapeutics market.
Currently, monoclonal antibodies targeting immunoglobulin E (IgE),
interleukin-4 (IL-4), interleukin-5 (IL-5) and their receptors have shown
promising results in clinical trials for treating allergic asthma. Companies
are also investing in developing therapies targeting cytokines like IL-33 and
thymic stromal lymphopoietin (TSLP) involved in allergic inflammation. Such
novel targeted therapies are expected to provide improved efficacy over
existing drugs with lesser side effects.
Porter's
Analysis
Threat of new entrants: The risk of new players entering the allergic asthma
therapeutics market is moderate as considerable capital investment is required
to develop new treatment alternatives and compete with established brands.
However, development of novel treatment options by biotech companies provide
opportunities.
Bargaining power of buyers: The bargaining power of buyers in the form of
patients and healthcare facilities is moderate. Asthma being a chronic
respiratory condition offers sustained revenues to pharmaceutical companies.
Bargaining power of suppliers: Suppliers of active pharmaceutical ingredients
and contract manufacturing organizations have moderate bargaining power given
the intellectual property and regulatory requirements around drug development.
Threat of new substitutes: Threat from substitute treatment options is moderate
as novel biologics and combination therapies continue to expand therapeutic
choices for allergic asthma.
Competitive rivalry: The allergic asthma therapeutics market witnesses high
competition due to presence of large pharmaceutical companies and steady
product pipeline of biologics.
Key Takeaways
The global allergic asthma therapeutics market is expected to witness high
growth over the forecast period owing to rising asthma prevalence globally.
North
America is expected to dominate the market over the forecast period owing to
high awareness regarding asthma treatment options and robust healthcare
infrastructure in the region.
Key
players operating in the allergic asthma therapeutics market are Ansarada Pty
Ltd., Brainloop AG (Diligent Corporation), CapLinked, Citrix Systems Inc.,
Datasite Global Corporation, DealRoom Inc., EthosData, Firmex Inc, FORDATA sp.
z o.o., iDeals Solutions Group, Intralinks Holdings Inc. (SS&C
Technologies), SecureDocs Inc., ShareVault (Pandesa Corporation) and SmartRoom
(BMC Group).
For More details on the topic:
Comments
Post a Comment